

**AHNCI Neurologic Oncology Program Tumor Board**

Friday, June 19, 2020

12:00-1:00 p.m.

Join Zoom Meeting

<https://zoom.us/j/519670691>

Meeting ID: 519 670 691

Dial by your location

+1 646 558 8656

**PASSWORD- 804637**

**Cases to be discussed**

|  |  |  |  |
| --- | --- | --- | --- |
| **Case**  | **De-identified patient** |  | **Presenter** |
| 1 | KR MRN: 11892658 | metastatic triple negative breast cancer diagnosed 07/2019. She has symptomatic intramedullary metastasis involving C7-T1. Patient just completed a course of XRT on 6/10/2020 at Magee Hospital. Dr Hilton had her evaluated on 5/28/2020 by neurosurgery, Dr Leonardo. | CH |
| 2 | BG MRN:  1264351 | 26 y/o male with Right hemispheric Pilocytic Astrocytoma of the hypothalamic-chiasmatic region, diagnosed 2001 (age 7 yo). Stable pituitary MRI 6/16/20. Presenting for radiology review. | TR |
| 3 | AR MRN:  10045942 | 49 y/o male with Recurrent Left Frontal Anaplastic astrocytoma, WHO grade 3, MGMT positive diagnosed 10/15/2014, recurrence on 4/10/2015.Stable MRI Brain 6/16/20. Presenting to review imaging. | TR |
| 4 | ML MRN:  11843750 | 53 y/o male with Left, frontotemporal  Glioblastoma, WHO Grade IV, MGMT unmethylated (0.26), IDH-1 Mutant, diagnosed 2/27/2020. S/p Temodar with concurrent XRT completed 5/19/20 with Dr. Renz. Enhancement noted on post treatment MRI Brain 6/16/20. Possible treatment effect? Presenting to review imaging. | TR |
| 5 | MB MRN:  780996 | 34 y/o male with Left Parietal Anaplastic Astrocytoma, IDH Mutant, MGMT unmethylated, diagnosed 2/15/2018.Presenting to review PET Brain 6/18/20. | TR |
| 6 | CR MRN:  5543114 | 40 y/o male with Left Temporal Glioblastoma, WHO Grade IV, MGMT unmethylated (0.09), IDH Wild type, diagnosed 5/10/2019. Palliative Gamma Knife completed 3/3 with 27 Gy on 1/15/2020 under the direction of Dr. Rodney Wegner at AGH. Patient currently on Carmustine and Rapamune. Presenting to review MRI Brain 6/15/20. | TR |
| 7 | DS MRN:  388423 | 50 y/o female with Right frontal diffuse Anaplastic Astrocytoma, WHO Grade 111, MGMT insufficient sample for testing, IDH mutant, diagnosed 02/05/2019. Metronomic Temodar 50 mg/m2 (80 mg) daily x 6 cycles. Initiated 6/17/2019 and Cycle #6 completed 12/12/2019. Currently on surveillance imaging only. Presenting to review MRI Brain 6/17/20. | TR |
| 8 | JB MRN:  1144202 | 58 y/o female with Pineal Meningioma, unresectable, diagnosed radiographically 12/2016. Definitive Empiric Radiotherapy with 33 fractions and 59.4 Gy completed 2/8/2019 by Dr. Valakh, WPH Radiation Oncology. Patient also has history of breast and cervical CA, currently in remission. Patient experiencing multiple daily seizure events, described as all 4 extremity shaking/intermittent urinary incontinence/LOC along with less frequent absence staring events. Presenting to discuss possible treatment plan. |  |
| 9 |  |  |  |
| 10 |  |  |  |
| 11 |  |  |  |
| 12 |  |  |  |
| 13 |  |  |  |

AHN CME Credit

**TEXT 412-301-9919**save this number to your contacts–
will use this **same** number every week to text your attendance

**Today’s SMS Code: VACMUB**

You must text within 24 hours of the start of tumor board. You will receive a text receipt and a link to confirm attendance and receive credit

Objectives: Upon completion of this activity, participants will have a better understanding of decision-making for complex Neurologic Oncology and be armed with clinical pathways to improve care.

Accreditation: Allegheny General Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement:Allegheny General Hospital designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)™*.  Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Disclosure: In accordance with the Accreditation Council for Continuing Medical Education (ACCME) and the policy of Allegheny General Hospital, presenters must disclose all relevant financial relationships, which in the context of their presentation(s), could be perceived as a real or apparent conflict of interest, (e.g., ownership of stock, honoraria or consulting fees). Any identifiable conflicts will be resolved prior to the activity. Any such relationships will be disclosed to the learner prior to the presentation(s).

Moderators and Presenters: Tulika Ranjan, MD and Stephen Karlovits, MD has nothing to disclose